Orionis Biosciences
Orionis Biosciences is a biotechnology company developing novel immunotherapies for cancer treatment using proprietary drug discovery platforms. The company has raised $79 million, including a Series C in 2022 with backing from Novartis and other healthcare investors.
The growth story
Orionis Biosciences grew from 38 to 67 employees between 2022 and 2026, raising $79M along the way, most recently a Series C in October 2022.
About
Orionis Biosciences develops biologics and small molecule therapies through its A-Kine and Allo-Glue platforms, which aim to reprogram disease states. Its pipeline focuses on cancer immunotherapies.
The company has 67 employees and maintains strong ties to Belgian research institutions, with many team members coming from Ghent University and VIB. Its $79 million funding includes participation from strategic investor Novartis.
Founders and leadership
Research dominates Orionis' organization, with 29 employees in that function. The company shows stability with a median tenure of 5 years among its 67-person team.
The Orionis Biosciences org chart
Nikolai Kley (Founder, President and CEO) leads 16 mapped leaders with 7 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 43 (+16% YoY), Business Development 8 (+60% YoY), Engineering 4 (+33% YoY), Program and Project Management 3 (+200% YoY).
Talent flow
Orionis recruits heavily from Ghent University (12 alumni) and VIB (7), with additional hires from cancer research centers like Dana-Farber. Alumni have moved to biotechs including argenx and Legend Biotech.
Most common previous employers of Orionis Biosciences staff: Ghent University (10), VIB (7), Forma Therapeutics (Now Novo Nordisk) (6), Dana-Farber Cancer Institute (3), KU Leuven (3), VIB-UGent (3). Former Orionis Biosciences employees most often moved to argenx (2), Kata (1), Massachusetts Technology Collaborative (1), V-Bio Ventures (1), Legend Biotech (1), PJT Partners (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Orionis Biosciences: Biotechnology (26), Molecular Biology (25), Western Blotting (23), Biochemistry (22), Life Sciences (20), Cell Culture (19), Cell Biology (18), Polymerase Chain Reaction (PCR) (17).
Where the team actually sits
Orionis Biosciences people are concentrated in Flemish Region, Belgium (22), Ghent Metropolitan Area (13), Greater Boston (7), Massachusetts, United States (5).
Search footprint
Orionis Biosciences attracts about 160 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 24 ranking keywords and lost 26 in the last period.
Frequently asked
Orionis Biosciences has 67 employees as of September 2026.
Orionis Biosciences has raised $79M in total, most recently a Series C round in October 2022.
Orionis Biosciences was founded in 2015 by Nikolai Kley.
Nikolai Kley (Founder, President and CEO) sits at the top of Orionis Biosciences's reporting structure, with 7 direct reports.
The most common previous employers of current Orionis Biosciences staff are Ghent University (10 people), VIB (7 people), Forma Therapeutics (Now Novo Nordisk) (6 people).
Former Orionis Biosciences employees most often move to argenx (2), Kata (1), Massachusetts Technology Collaborative (1).
Orionis Biosciences attracts about 160 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among Orionis Biosciences staff are Biotechnology, Molecular Biology, Western Blotting, Biochemistry, Life Sciences.
Orionis Biosciences staff are concentrated in Flemish Region, Belgium (22), Ghent Metropolitan Area (13), Greater Boston (7).
Orionis Biosciences has about 43 people in Research, up 16% over the past year, as of September 2026.
Orionis Biosciences has about 8 people in Business Development, up 60% over the past year, as of September 2026.
Computed from 53 current and 22 former Orionis Biosciences profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.